Avances terapéuticos en el tratamiento del cáncer de ovario: OLAPARIB: primer inhibidor de PARP - page 19

December, 2014

Protocol 42: Advanced, recurrent disease (USA)

Protocol 19: Maintenance therapy (Europe)

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,9,10,11,12,13,14,15,16,17,18 20,21,22,23,24,25,26,27,28,29,...33